Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A minibody that recognizes a human leukocyte antigen (HLA).

2. (Withdrawn) The minibody of claim 1, wherein the HLA is an HLA class I.

3. (Withdrawn) The minibody of claim 2, wherein the HLA class I is an HLA-A.

4. (Withdrawn) A minibody derived from a 2D7 antibody.

5. (Withdrawn) The minibody of any one of claims 1 to 4, wherein the minibody is a diabody.

6. (Withdrawn) A minibody of any one of (a) to (d):

(a) a minibody comprising the amino acid sequence of SEQ ID NO: 6;

(b) a minibody functionally equivalent to the minibody of (a), and comprising an amino acid sequence with a substitution, insertion, deletion and/or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 6;

(c) a minibody comprising the amino acid sequences of CDRs of SEQ ID NOs: 2 and 4; and

(d) a minibody functionally equivalent to the minibody of (c), and comprising an amino acid sequence with a substitution, insertion, deletion and/or addition of one or more amino acids in the amino acid sequence of the CDRs of SEQ ID NOs: 2 and 4.

7-12. (Cancelled)

13. (Withdrawn) A cell death-inducing agent, comprising as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

14. (Withdrawn) The cell death-inducing agent of claim 13 that induces cell death of a B cell or T cell.

15. (Withdrawn) The cell death-inducing agent of claim 14, wherein the B cell or T cell is an activated B cell or activated T cell.

16. (Withdrawn) A cell growth-suppressing agent comprising as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

17. (Withdrawn) An antitumor agent comprising as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

18. (Withdrawn) The antitumor agent of claim 17, wherein the tumor is a blood tumor.

19. (Withdrawn) A therapeutic agent for an autoimmune disease, wherein the therapeutic agent comprises as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

20. (Withdrawn) The cell death-inducing agent of any one of claims 13 to 15, wherein the antibody is a diabody.

21. (Withdrawn) The cell growth-suppressing agent of claim 16, wherein the antibody is a diabody.

22. (Withdrawn) The antitumor agent of claim 17 or 18, wherein the antibody is a diabody.

23. (Withdrawn) The therapeutic agent for autoimmune disease of claim 19, wherein the antibody is a diabody.

24. (New) A method for producing an HLA-recognizing minibody, the method comprising:

(a) identifying a whole antibody that recognizes HLA; and

(b) producing a minibody version of the antibody of (a),

wherein the minibody has an increased cytotoxic activity compared to the antibody of (a).

25. (New) The method of claim 24, further comprising:

(c) assaying a cytotoxic activity of the minibody.

26. (New) The method of claim 25, wherein the HLA is an HLA class I antigen.

27. (New) The method of claim 26, wherein the HLA class I antigen is an HLA-A antigen.

28. (New) The method of claim 25, wherein the antibody of (a) is an IgG.

29. (New) The method of claim 25, wherein the minibody comprises a Fab, a Fab', a F(ab')2, a Fv, an scFv, or a diabody.

30. (New) The method of claim 25, wherein the minibody comprises an scFv or a diabody.

31. (New) The method of claim 30, wherein the scFv or the diabody comprises CDRs derived from a heavy chain variable region and a light chain variable region of the antibody of (a).

32. (New) The method of claim 25, wherein the minibody is a diabody comprising two scFv.

33. (New) The method of claim 25, wherein the cytotoxic activity is a cell death-inducing activity.

34. (New) The method of claim 25, wherein the cytotoxic activity is a cell growth-suppressing activity.

35. (New) A method of producing a minibody, the CDRs of which are derived from the CDRs of an HLA-recognizing whole antibody, wherein the minibody has a level of cytotoxic activity greater than that of the whole antibody, the method comprising:

(a) providing a DNA encoding the minibody;

(b) expressing the minibody from the DNA;

(c) confirming that the expressed minibody possesses cytotoxic activity greater than that of the whole antibody.

36. (New) The method of claim 35, wherein the minibody comprises human framework regions.

37. (New) The method of claim 35, wherein the whole antibody is a human antibody.

38. (New) The method of claim 35, wherein the whole antibody is a non-human antibody and the minibody is humanized.

39. (New) The method of claim 35, wherein the HLA is an HLA class I antigen.

40. (New) The method of claim 39, wherein the HLA class I antigen is an HLA-A antigen.

41. The method of claim 35, wherein the minibody comprises an scFv or a diabody.

42. (New) The method of claim 35, wherein the cytotoxic activity is a cell death-inducing activity.

43. (New) The method of claim 35, wherein the cytotoxic activity is a cell growth-suppressing activity.

44. (New) An HLA-recognizing scFV or diabody produced by the method of claim 41.

45. (New) An HLA-recognizing minibody produced by the method of claim 25.